Clinical Trial Update: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacokinetics of HBI-002, an oral carbon monoxide–releasing therapeutic, in healthy volunteers; the trial is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Sickle Cell Disease

Drugs mentioned

• HBI-002

Snippet

Sponsor: Hillhurst Biopharmaceuticals, Inc. | Conditions: Anemia, Sickle Cell | Phase 1 | Status: COMPLETED | Results posted: 2025-05-23